NRx Pharmaceuticals (NRXP) said Tuesday that it is initiating clinical training of Nation of Georgia ICU physicians, in the use of intravenous ZYESAMI or Aviptadil- acetate for emergency use in patients suffering with Critical COVID-19, and inhaled ZYESAMI for use in phase 2/3 clinical trials, for patients suffering with COVID-19.
In addition, the company said that it has extended its ongoing phase 2/3 trial of inhaled ZYESAMI to Georgia, in Partnership with Denk Pharma (Georgia), and Cromos, LLC.
NRx expects to ship clinical drug supplies to Georgia within two weeks. The development of intravenous Aviptadil-acetate, in non-GMP form was partially-funded by a collaboration agreement with Relief Therapeutics.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.